USNA Usana Health Sciences Inc

  1. Stocks
  2. Consumer Defensive
  3. NYSE: USNA

Price (delayed)

$19.225

Market cap

$354.95M

P/E Ratio

40.05

Dividend/share

N/A

EPS

$0.48

Enterprise value

$206.2M

?
Relative Growth: Rel. Growth: 23
Relative Strength: Rel. Strength: 26
Relative Valuation: Rel. Valuation: 72
Relative Profitability: Rel. Profitability: 53

USANA prides itself in providing consumers the highest quality nutritional products in the world. From its award-winning supplements to its innovative skincare line, USANA has proven for more than 25 ...

Highlights
USNA's debt is down by 39% YoY
The quick ratio has grown by 20% from the previous quarter and by 12% YoY
The price to earnings (P/E) is 111% higher than the 5-year quarterly average of 18.7 and 33% higher than the last 4 quarters average of 29.6
USNA's net income has dropped by 75% year-on-year and by 18% since the previous quarter
Sector: Consumer Defensive
Industry: Packaged Foods
Website: http://www.usana.com
Peers: NATR NUS MTEX IPAR

Key stats

What are the main financial stats of USNA

USNA stock price

How has the Usana Health Sciences stock price performed over time
Intraday
1.72%
1 week
1.13%
1 month
2.59%
1 year
-36.66%
YTD
-2.06%
QTD
10.05%

Financial performance

How have Usana Health Sciences's revenue and profit performed over time
Revenue
$925.94M
Gross profit
$718.09M
Operating income
$35.64M
Net income
$8.87M
Gross margin
77.6%
Net margin
1%
USNA's net margin has plunged by 75% YoY and by 17% from the previous quarter
USNA's net income has dropped by 75% year-on-year and by 18% since the previous quarter
Usana Health Sciences's operating margin has decreased by 42% YoY and by 5% QoQ
The operating income has declined by 38% year-on-year and by 4.8% since the previous quarter

Price vs fundamentals

How does USNA's price correlate with its fundamentals

Growth

What is Usana Health Sciences's growth rate over time

Valuation

What is Usana Health Sciences stock price valuation
USNA P/E details
P/E
40.05
P/B
0.65
P/S
0.38
EV/EBIT
5.07
EV/EBITDA
2.58
EV/Sales
0.22
The price to earnings (P/E) is 111% higher than the 5-year quarterly average of 18.7 and 33% higher than the last 4 quarters average of 29.6
The EPS has plunged by 74% YoY and by 17% from the previous quarter
USNA's P/B is 72% below its 5-year quarterly average of 2.3 and 20% below its last 4 quarters average of 0.8
The company's equity rose by 2.6% YoY
USNA's price to sales (P/S) is 62% less than its 5-year quarterly average of 1.0 and 24% less than its last 4 quarters average of 0.5
USNA's revenue is up by 6% year-on-year

Efficiency

How efficient is Usana Health Sciences business performance
Usana Health Sciences's ROA has plunged by 74% YoY and by 20% from the previous quarter
The ROE has plunged by 74% YoY and by 15% from the previous quarter
The company's return on invested capital has shrunk by 50% YoY and by 8% QoQ
The ROS has contracted by 42% YoY and by 2.2% from the previous quarter

Dividends

What is USNA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for USNA.

Financial health

How did Usana Health Sciences financials performed over time
The current ratio has increased by 22% YoY and by 12% from the previous quarter
The quick ratio has grown by 20% from the previous quarter and by 12% YoY
USNA's debt is 97% less than its equity
USNA's debt is down by 39% YoY
The debt to equity has contracted by 25% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.